A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Novartis
Arcus Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Pfizer
Astellas Pharma Inc
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Baylor Research Institute
University of Miami
Genentech, Inc.
Mayo Clinic
City of Hope Medical Center
Massachusetts General Hospital
Enliven Therapeutics
Massachusetts General Hospital
The Methodist Hospital Research Institute
Cancer Trials Ireland
University Health Network, Toronto
City of Hope Medical Center
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Tanta University
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
Ono Pharmaceutical Co., Ltd.
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Eli Lilly and Company
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Servier
National University Hospital, Singapore
National Cancer Institute (NCI)
Shanghai Zhongshan Hospital
OHSU Knight Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
Sumitomo Pharma America, Inc.